Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Oct 31:42:84-86.
doi: 10.1016/j.jdcr.2023.10.012. eCollection 2023 Dec.

Recalcitrant lichen planus pigmentosus treated with topical ruxolitinib

Hannah L Cornman  1 , Elena Wei  1 , Jaya Manjunath  1 , Emily Z Ma  1 , Brenda Umenita Imo  1 , Alexander L Kollhoff  1 , Anusha Kambala  1 , Jingyi Zhang  1 , Shivani S Patel  2 , Shawn G Kwatra  1   3
Affiliations
Case Reports

Recalcitrant lichen planus pigmentosus treated with topical ruxolitinib

Hannah L Cornman et al. JAAD Case Rep. .
No abstract available

Keywords: JAK inhibitor; cream; hyperpigmentation; janus kinase inhibitor; lichen planus pigmentosus; recalcitrant; ruxolitinib; topical.

PubMed Disclaimer

Conflict of interest statement

Dr Kwatra is an advisory board member/consultant for Abbvie, Aslan Pharmaceuticals, Arcutis Biotherapeutics, Castle Biosciences, Celldex Therapeutics, Galderma, Genzada Pharmaceuticals, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi. All others declare no conflict of interest to declare. Dr Patel is an advisory board member/consultant for Arcutis Biotherapeutics, Dermavant, Incyte, Sanofi, and Regeneron.

Figures

Fig 1
Fig 1
Clinical improvement of lichen planus pigmentosus skin lesions during treatment with topical ruxolitinib 1.5% cream. A, Clinical photographs of skin lesions at initial presentation with gray-violaceous hyperpigmented macules coalescing into patches on the bilateral cheeks extending to the temples and anterior neck. B, Significantly reduced hyperpigmentation and smaller affected area after 3 months of treatment. C, Further reduction of hyperpigmentation after 9 months of treatment.
See this image and copyright information in PMC

References

    1. Robles-Méndez J.C., Rizo-Frías P., Herz-Ruelas M.E., Pandya A.G., Ocampo Candiani J. Lichen planus pigmentosus and its variants: review and update. Int J Dermatol. 2018;57(5):505–514. doi: 10.1111/ijd.13806. - DOI - PubMed
    1. Al-Mutairi N., El-Khalawany M. Clinicopathological characteristics of lichen planus pigmentosus and its response to tacrolimus ointment: an open label, non-randomized, prospective study. J Eur Acad Dermatol Venereol. 2010;24(5):535–540. doi: 10.1111/j.1468-3083.2009.03460.x. - DOI - PubMed
    1. Wenzel J., Tüting T. An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in “interface dermatitis.”. J Invest Dermatol. 2008;128(10):2392–2402. doi: 10.1038/jid.2008.96. - DOI - PubMed
    1. Motamed-Sanaye A., Khazaee Y.F., Shokrgozar M., Alishahi M., Ahramiyanpour N., Amani M. JAK inhibitors in lichen planus: a review of pathogenesis and treatments. J Dermatolog Treat. 2022;33(8):3098–3103. doi: 10.1080/09546634.2022.2116926. - DOI - PubMed
    1. Tavakolpour S., Mahmoudi H., Abedini R., Kamyab Hesari K., Kiani A., Daneshpazhooh M. Frontal fibrosing alopecia: an update on the hypothesis of pathogenesis and treatment. Int J Womens Dermatol. 2019;5(2):116–123. doi: 10.1016/j.ijwd.2018.11.003. - DOI - PMC - PubMed

Publication types

LinkOut - more resources